Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial ResultsGlobeNewsWire • 11/12/25
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/04/25
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study DataZacks Investment Research • 10/10/25
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should KnowZacks Investment Research • 10/06/25
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross ProceedsGlobeNewsWire • 10/03/25
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profileGlobeNewsWire • 10/03/25
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/13/25
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone RoyaltiesGlobeNewsWire • 06/25/25
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial ResultsGlobeNewsWire • 05/13/25
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 05/06/25
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 03/11/25
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of DirectorsGlobeNewsWire • 03/03/25
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewsWire • 02/27/25
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/05/25
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future GrowthGlobeNewsWire • 09/11/24
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law FirmAccesswire • 08/19/24
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law FirmAccesswire • 08/18/24
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law FirmAccesswire • 08/17/24
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law FirmAccesswire • 08/16/24